Has Jon Robken, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,172 in general payments to Jon Robken, MD across 92 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jon Robken, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jon Robken, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jon Robken, MD

Cardiovascular Disease · Davenport, IANPI 1750360764

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Abbott at 30.3% of the total.

$2,172in general payments, 2019–2025

Across 92 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$659
Edwards Lifesciences$246
Shockwave Medical, Inc$197
Abiomed$187
Boston Scientific$183
Astellas Pharma US Inc$174
plus $526 from 14 others

$6,247in research payments, 2019–2025

Across 4 payments — averaging $1561.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Cordis Corporation$6K

What the payments were for

Food & beverage$1,99892%
Education$1748%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	35	$659
Edwards Lifesciences	5	$246
Shockwave Medical, Inc	12	$197
Abiomed	7	$187
Boston Scientific	4	$183
Astellas Pharma US Inc	2	$174
Inari Medical, Inc.	6	$156
Teleflex LLC	3	$63
Livanova USA, Inc.	1	$56
Cook Medical LLC	3	$48
Penumbra, Inc.	2	$31
Biosense Webster, Inc.	1	$28
Bard Peripheral Vascular, Inc.	2	$27
Johnson & Johnson	2	$26
Biotronik Inc.	1	$18
Cardiovascular Systems Inc.	2	$17
Surmodics, Inc.	1	$15
W. L. Gore & Associates, Inc.	1	$15
Medtronic	1	$14
Philips North America LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CROSSBOSS$140
Edwards SAPIEN 3 Transcatheter Heart Valve$108

How this compares

$2,172 in reported general payments places this provider in the 65th percentile of 142 cardiovascular disease providers in Iowa.

See all cardiovascular disease providers in Iowa →

Medicare billing

Part B allowed, 2024

$585,491

Medicare patients

1,441

Services billed

6,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	36	$42,138
EntrestoSacubitril/Valsartan	18	$15,764
ClopidogrelClopidogrel Bisulfate	207	$1,308
Metoprolol Succinate	43	$304
Atorvastatin Calcium	32	$289
Furosemide	47	$183
Isosorbide Mononitrate ErIsosorbide Mononitrate	19	$150
Amlodipine Besylate	32	$148
Metoprolol Tartrate	27	$106
Potassium Chloride	15	$106
Lisinopril	17	$44
Amoxicillin	18	$16

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Davenport

Gursukhman Deep SidhuDavenport$60K
Brian OlshanskyIowa City$219K
Troy HounshellWest Des Moines$164K
Enrico MartinWest Des Moines$113K
Suzanne FeigofskyWest Des Moines$59K
Tyler RasmussenCedar Rapids$37K
Jennifer RobinsonIowa City$37K
Matthew McMahonCedar Rapids$35K
Craig StarkDes Moines$28K
Tauseef KhanDubuque$23K

See the full list for Iowa →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →